OVARIAN CANCER

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

Abstract: The FDA approved a new treatment of advanced ovarian cancer on the first line of the short-term treatment programs, in the treatment of cisplatin infusion again, Bristol-Myers Squibb pharmaceutical factories paclitaxel (Taxol) 3 hours.

The United States Food and Drug Administration (FDA) approved a new treatment of advanced ovarian cancer on the first line of the short-term treatment programs, in the treatment of cisplatin injection again, Bristol-Myers Squibb pharmaceutical factories paclitaxel (Taxol) 3 hours.

Tags: administration, age, anti, blood, breast, cancer, cell, cells, cisplatin, clinical, drug, drugs, eat, fat, grams, head, infusion, injection, neck, ovarian, paclitaxel, patients, radiotherapy, reduce, risk, study, taxol, therapy, toxicity, treatment, women

A benign ovarian tumors young patients affected Annex tumor resection or stripped of. If both bilateral ovarian tumors, should fight to retain part of normal ovarian tissue. Before post-clearance as abdominal specimens suspected malignant sent frozen biopsy. Patients before and after menopause to be hysterectomy and bilateral resection of the Annex to activities.

2, malignant ovarian tumor treatment to the main, supplemented by chemotherapy, and radiotherapy.

(1) to general surgery for hysterectomy, bilateral Annex and the omentum resection. Patients with advanced cancer should be possible for the transfer to that reduction of tumor cells. As for retroperitoneal lymph node removal of the therapeutic value can not be determined.

Tags: abdominal, age, annex, anti, benign, cancer, cell, cells, chemotherapy, cisplatin, days, dose, drug, drugs, eat, ert, exploration, gene, grams, infusion, injection, intraperitoneal, intravenous, irradiation, lymph, malignant, node, ovarian, patients, protein, radiation, radiotherapy, rate, reduce, resection, residual, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors, usually

Taxol is more 1990s, the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, chemotherapy, cisplatin, confidence, days, diet, dose, drug, drugs, eat, ert, gene, group, growth, incidence, infusion, injection, intravenous, life, metastasis, method, ovarian, paclitaxel, pain, patients, poor, psychological, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

"Nursing Care of Patients Treated With Combination Oophoroma of Taxolr and Platinum" ovarian cancer in the female genital cancer incidence rate of the two, but the mortality rate is the one. According to information at home and abroad, the survival rate of patients 5a about 30%, 70% have advanced at diagnosis [1]. Currently the disease is a better treatment after surgery and adjuvant chemotherapy. I Branch in 1996 -1997, will Taxol and cisplatin in the treatment of ovarian cancer <BR> made good effect, even on the platinum resistance there are still 20% to 30% effective. Now Taxol treatment care summarized as follows:
A clinical data and methods
1.1 clinical data: 12 patients had been diagnosed with ovarian cancer. Age 18 to 68 years old, with an average age of 43 years. Thailand used in the treatment of a total of 24 courses, the average two courses. Only two courses for Taxol alone, the rest are combined, each treatment separated three weeks to four weeks.
1.2 treatment:
1.2.1 before chemotherapy treatment: 6 hours respectively before treatment, 12 hours of oral dexamethasone 20 mg, in the half-hour before administration of oral and intravenous diphenhydramine 50 mg and cimetidine 300 mg to prevent the occurrence of allergic reactions.
1.2.2 drug preparation: Thailand concentrated on the use of PVC with a syringe preparation will liquid two phthalic acid ethyl of increase [2]. It increases in drug use should be used glass and stainless steel syringe needles, and the infusion of special filters are allocated are spent. As the Taxol is a cell-like anti-cancer drugs, so nurses in the preparation and administration must pay attention to self-protection, gloves, masks, if the skin or mucosa by pollution, should be thoroughly cleaned immediately with soap or water rinse [2].

Tags: administration, age, anti, cancer, care, cell, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, eat, incidence, infusion, intravenous, method, ovarian, patients, rate, skin, surgery, survival, taxol, therapy, treatment

According to an obstetrics and gynecology oncology groups (GOG) study said that the smaller Phase III epithelial ovarian cancer patients, carboplatin and Taxol toxicity smaller, easier to use, the effect is less than cisplatin plus paclitaxel.

The non-randomized study data show that in advanced epithelial ovarian cancer, carboplatin and paclitaxel very effective, but less than the toxicity of cisplatin-based drugs, but its smaller, have unresectable Stage III cancer effects remain unknown. To this end, Philadelphia Fox Kaiser Cancer Center Aozhuoershi (Robert F. Ozols), and colleagues conducted a test to detect carboplatin and paclitaxel combined with cisplatin is secondary. 792 patients participated in this study, 400 were randomly assigned cisplatin (75 mg/m2) and paclitaxel (135 mg/m2) 24-hour infusion (group I), 392 with carboplatin (area under the curve of 7.5) and paclitaxel (175 mg / m2) 3-hour infusion (Group II). The two groups were 85% and 87% of the patients completed six cycles of treatment.

Tags: age, blood, cancer, carboplatin, cell, cisplatin, clinical, drug, drugs, eat, ert, group, groups, gynecological, infusion, ovarian, paclitaxel, patients, rate, second, study, survival, taxol, time, toxicity, treatment

Whitney physicians that cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer treatment should become the new standard.

Carboplatin / taxol treatment programs, and the current phase III epithelial ovarian tumors standard chemotherapy - cisplatin / paclitaxel, the same as its efficacy, toxicity small. Experts believe that the program should become a new standard treatment programs.

Combination of paclitaxel and cisplatin, paclitaxel must be sustained 24-hour infusion, and Taxol and carboplatin compatibility, 3-hour infusion of paclitaxel can, thus reducing low toxic side effects to a large extent.

Tags: age, cancer, carboplatin, cases, cause, chemotherapy, cisplatin, clinical, drug, early, eat, ert, exploration, grams, group, infusion, injection, method, ovarian, paclitaxel, pain, patients, prognosis, rate, residual, risk, second, study, surgery, survival, taxol, therapy, toxicity, treatment, tumor, tumors